<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03636438</url>
  </required_header>
  <id_info>
    <org_study_id>301OTC02</org_study_id>
    <secondary_id>2018-000156-18</secondary_id>
    <nct_id>NCT03636438</nct_id>
  </id_info>
  <brief_title>Long Term Follow Up to Evaluate DTX301 in Adults With Late-Onset OTC Deficiency</brief_title>
  <acronym>CAPtivate</acronym>
  <official_title>A Long-Term Follow-up Study to Evaluate Safety and Efficacy of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ultragenyx Pharmaceutical Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ultragenyx Pharmaceutical Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the long-term safety of DTX301 following a single intravenous (IV) dose in adults
      with late-onset ornithine transcarbamylase (OTC) deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study 301OTC02 is a long-term follow-up study to evaluate the safety and efficacy of
      adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of human OTC in adults
      with late-onset OTC deficiency. Only subjects who complete Study 301OTC01 (NCT02991144) are
      eligible to participate in Study 301OTC02.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">August 30, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 260 weeks following DTX301 administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in the Ureagenesis Rate</measure>
    <time_frame>Baseline (average of Screening and Day 1) up to 260 weeks following DTX301 administration</time_frame>
    <description>Sodium acetate is used as a tracer to measure the rate of ureagenesis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Over Time in 24-Hour Area Under the Curve for Plasma Ammonia</measure>
    <time_frame>Baseline (Day 0 of Study 301OTC01) up to 260 weeks following DTX301 administration</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Ornithine Transcarbamylase (OTC) Deficiency</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>No Intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects 18 years of age or older with OTC previously enrolled in Study 301OTC01
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Completed the Week 52 visit in Study 301OTC01.

          2. Willing and able to provide written informed consent.

          3. Willing, able, and committed to comply with scheduled study site visits, study
             procedures, and requirements.

        Exclusion Criteria:

          1. Planned or current participation in another interventional clinical study that may
             confound the efficacy or safety evaluation of DTX301 during the duration of this
             study.

          2. Any clinically significant medical condition that, in the opinion of the investigator,
             would pose a risk to subject safety or would impede the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ultragenyx Pharmaceuticals Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago De Compostela</city>
        <state>Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Cruces. Servicio de Pediatria</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, Department of Endocrinology</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene therapy</keyword>
  <keyword>OTC Deficiency</keyword>
  <keyword>Urea Cycle Disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

